Ontology highlight
ABSTRACT: Purpose
BARD1 is a BRCA1-binding partner with tumor suppressive properties. Aberrant splice variants of BARD1 have been detected in various cancers, and it has been postulated that the presence of some splice variants is cancer specific. This is the first study assessing BARD1 expression patterns and correlation with clinical outcome in colon cancer.Experimental design
We analyzed colon cancer samples for the occurrence of BARD1 splice variants, characterized novel BARD1 splice variants, and quantified the mRNA expression levels of these isoforms in primary colon cancers and their corresponding normal tissue. We tested the correlation of full-length BARD1 protein expression and clinical outcome in primary colon cancer samples.Results
In addition to the full-length B
SUBMITTER: Sporn JC
PROVIDER: S-EPMC3372413 | biostudies-literature | 2011 Aug
REPOSITORIES: biostudies-literature